Cargando…

Comparison of Glucose-Lowering Drugs as Second-Line Treatment for Type 2 Diabetes: A Systematic Review and Meta-Analysis

Background: Multiple glucose-lowering drugs are available as add-ons to metformin for a second-line treatment for type 2 diabetes. However, no systematic and comparative data are available for them in China. We aimed to compare the effects of glucose-lowering drugs added to metformin in China. Metho...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gu, Shuyan, Hu, Xiaoqian, Zhen, Xuemei, Shi, Lizheng, Shao, Hui, Sun, Xueshan, Gu, Yuxuan, Huang, Minzhuo, Dong, Hengjin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Systematic Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9504435/ https://www.ncbi.nlm.nih.gov/pubmed/36143082 http://dx.doi.org/10.3390/jcm11185435

Ejemplares similares

Choice of Glucose-Lowering Drugs as Initial Monotherapy for Type 2 Diabetes Patients with Contraindications or Intolerance to Metformin: A Systematic Review and Meta-Analysis
por: Gu, Shuyan, et al.
Publicado: (2022)

Measurement and analysis of equity in health: a case study conducted in Zhejiang Province, China
por: Sun, Xueshan, et al.
Publicado: (2018)

Potential gains in health-adjusted life expectancy from reducing four main non-communicable diseases among Chinese elderly
por: Hu, Xiaoqian, et al.
Publicado: (2019)

Outpatient health-seeking behavior of residents in Zhejiang and Qinghai Province, China
por: Huang, Minzhuo, et al.
Publicado: (2019)

A comparative study of catastrophic health expenditure in Zhejiang and Qinghai province, China
por: Zhen, Xuemei, et al.
Publicado: (2018)

Social Determinants of Health-Related Quality of Life among Residents in Zhejiang and Qinghai, China
por: Gu, Yuxuan, et al.
Publicado: (2019)

Trends in Cognitive Function Among Chinese Elderly From 1998 to 2018: An Age-Period-Cohort Analysis
por: Hu, Xiaoqian, et al.
Publicado: (2021)

Trends in activities of daily living disability among Chinese older adults from 1998 to 2018: an age-period-cohort analysis
por: Hu, Xiaoqian, et al.
Publicado: (2022)

Chinese Minority Perceives the Doctor-Patient Relationship Differently: A Cultural and Economic Interpretation
por: Yang, Qian, et al.
Publicado: (2019)

Osteoarthritis in the Middle-Aged and Elderly in China: Prevalence and Influencing Factors
por: Sun, Xueshan, et al.
Publicado: (2019)

Comparison of Glucose Lowering Effect of Metformin and Acarbose in Type 2 Diabetes Mellitus: A Meta-Analysis
por: Gu, Shuyan, et al.
Publicado: (2015)

Choice across 10 pharmacologic combination strategies for type 2 diabetes: a cost-effectiveness analysis
por: Gu, Shuyan, et al.
Publicado: (2020)

Cost-utility analysis of imrecoxib compared with diclofenac for patients with osteoarthritis
por: Sun, Xueshan, et al.
Publicado: (2021)

Cost-Effectiveness of Saxagliptin versus Acarbose as Second-Line Therapy in Type 2 Diabetes in China
por: Gu, Shuyan, et al.
Publicado: (2016)

Clinical and economic impact of methicillin-resistant Staphylococcus aureus: a multicentre study in China
por: Zhen, Xuemei, et al.
Publicado: (2020)

The Quality of Caregivers for the Elderly in Long-Term Care Institutions in Zhejiang Province, China
por: Zeng, Yuhang, et al.
Publicado: (2019)

Clinical and Economic Burden of Carbapenem-Resistant Infection or Colonization Caused by Klebsiella pneumoniae, Pseudomonas aeruginosa, Acinetobacter baumannii: A Multicenter Study in China
por: Zhen, Xuemei, et al.
Publicado: (2020)

Modeling the Cost-effectiveness of Esophageal Cancer Screening in China
por: Li, Yuanyuan, et al.
Publicado: (2020)

Economic burden of antibiotic resistance in China: a national level estimate for inpatients
por: Zhen, Xuemei, et al.
Publicado: (2021)

Correction to: Economic burden of antibiotic resistance in China: a national level estimate for inpatients
por: Zhen, Xuemei, et al.
Publicado: (2021)

The Clinical and Economic Impact of Antibiotic Resistance in China: A Systematic Review and Meta-Analysis
por: Zhen, Xuemei, et al.
Publicado: (2019)

Cognitive and physical function of people older than 80 years in China from 1998 to 2014
por: Hu, Xiaoqian, et al.
Publicado: (2018)

Economic burden of antibiotic resistance in ESKAPE organisms: a systematic review
por: Zhen, Xuemei, et al.
Publicado: (2019)

Clinical and Economic Impact of Third-Generation Cephalosporin-Resistant Infection or Colonization Caused by Escherichia coli and Klebsiella pneumoniae: A Multicenter Study in China
por: Zhen, Xuemei, et al.
Publicado: (2020)

The Disease and Economic Burdens of Esophageal Cancer in China from 2013 to 2030: Dynamic Cohort Modeling Study
por: Li, Yuanyuan, et al.
Publicado: (2022)

Cost-Effectiveness of Dapagliflozin versus Acarbose as a Monotherapy in Type 2 Diabetes in China
por: Gu, Shuyan, et al.
Publicado: (2016)

Effects of novel glucose-lowering drugs on the lipid parameters: A systematic review and meta-analysis
por: Dar, Sophia, et al.
Publicado: (2022)

Lower Limb Biomechanics during the Topspin Forehand in Table Tennis: A Systemic Review
por: He, Yuqi, et al.
Publicado: (2022)

Comparison of Second-Line Treatments for Patients with Platinum-Resistant Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Systematic Review and Bayesian Network Meta-Analysis
por: He, Yan, et al.
Publicado: (2022)

Second-line glucose-lowering drugs added to metformin and the risk of hospitalization for heart failure: A nationwide cohort study
por: Lee, Su Jin, et al.
Publicado: (2019)

Continuous Subcutaneous Insulin Infusion (CSII) Combined with Oral Glucose-Lowering Drugs in Type 2 Diabetes: A Systematic Review and Network Meta-Analysis of Randomized, Controlled Trials
por: Li, Hui, et al.
Publicado: (2022)

Cardiovascular and Renal Effectiveness of GLP-1 Receptor Agonists vs. Other Glucose-Lowering Drugs in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Real-World Studies
por: Caruso, Irene, et al.
Publicado: (2022)

Second-line treatment in patients with advanced extra-pulmonary poorly differentiated neuroendocrine carcinoma: a systematic review and meta-analysis
por: McNamara, Mairéad G., et al.
Publicado: (2020)

Comparative effectiveness of second line glucose lowering drug treatments using real world data: emulation of a target trial
por: Deng, Yihong, et al.
Publicado: (2023)

First- and Second-Line Treatments for Patients with Advanced Hepatocellular Carcinoma in China: A Systematic Review
por: Zhang, Lan, et al.
Publicado: (2022)

Youth Distance Running and Lower Extremity Injury: A Systematic Review
por: Paz, Tatiana, et al.
Publicado: (2021)

Second-Generation Antipsychotic Drugs for Patients with Schizophrenia: Systematic Literature Review and Meta-analysis of Metabolic and Cardiovascular Side Effects
por: Rognoni, Carla, et al.
Publicado: (2021)

Bariatric surgery, novel glucose-lowering agents, and insulin for type 2 diabetes and obesity: Bayesian network meta-analysis of randomized controlled trials
por: Wu, Tingting, et al.
Publicado: (2023)

Adverse events in second- and third-line treatments for acute and chronic graft-versus-host disease: systematic review
por: Velickovic, Vladica M., et al.
Publicado: (2020)

Clozapine as a first‐ or second‐line treatment in schizophrenia: a systematic review and meta‐analysis
por: Okhuijsen‐Pfeifer, C., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_2fjmrr3nd3jmljm0n4o5v7p278